Cardiol Therapeutics Inc(CRDL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.25 | Insider Own | 2.93% | Shs Outstand | 120.7M | Perf Week | - |
| Market Cap | 0.14B | Forward P/E | - | EPS next Y | 28.72% | Insider Trans | - | Shs Float | 117.1M | Perf Month | -30.77% |
| Enterprise Value | 0.12B | PEG | - | EPS next Q | -0.06 | Inst Own | 25.59% | Short Float | 2.43% | Perf Quarter | -3.31% |
| Income | -0.02B | P/S | - | EPS this Y | -12.78% | Inst Trans | 2.88% | Short Ratio | 2.04 | Perf Half Y | -10.69% |
| Sales | 0.00B | P/B | 8.01 | EPS next 5Y | 72.39% | ROA | -139.86% | Short Interest | 2.84M | Perf YTD | 22.67% |
| Book/sh | 0.15 | P/C | 7.68 | EPS past 3/5Y | 9.88% 11.6% | ROE | -192.95% | 52W High | -50% ($2.34) | Perf Year | - |
| Cash/sh | 0.15 | P/FCF | - | Sales past 3/5Y | - | ROIC | -145.37% | 52W Low | 32.95% ($0.88) | Perf 3Y | 39.29% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 28.85% | Gross Margin | - | Volatility(W/M) | 4.01% 6.32% | Perf 5Y | -71.11% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.08 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.55 | EPS Q/Q | 47.67% | Profit Margin | - | RSI (14) | 33.51 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.55 | Sales Q/Q | - | SMA20 | -3.86% ($1.22) | Beta | 0.98 | Target Price | $7.89 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/13 | SMA50 | -29.22% ($1.65) | Rel Volume | 0.32 | Prev Close | $1.14 |
| Employees | 23 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 48.49% - | SMA200 | -10.12% ($1.3) | Avg Volume(3M) | 1.40M | Price | $1.17 |
| IPO | 2019/1/15 | Option/Short | Yes/Yes | Trades | 642 | Volume | 450,625 | Change | 2.63% |
🫀 Cardiol Therapeutics is a clinical-stage life sciences company developing anti-inflammatory therapeutics that target inflammation and fibrosis in heart disease. Its lead candidate, CardiolRx, is being advanced in recurrent pericarditis, myocarditis, and heart failure, and is based on a mechanism that modulates the inflammasome pathway to address cardiovascular diseases with significant unmet need.
Over the past 1 year, on the lower side
50% below its 1-year high.
Traded less than usual. That is 32% of its average volume.
CRDL has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -12.8% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -71.1%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 25.6%.
Tap to view numbers
It ranks #54 of 83 in the industry
Based on market cap of $141M.
GLAS#52 Glass House Brands Inc $174M PER - 
DERM#53 Journey Medical Corp $145M PER - CRDL#54 Cardiol Therapeutics Inc $141M PER - 
OGI#55 Organigram Global Inc $135M PER 2.1 
BGM#56 BGM Group Ltd $130M PER - 
FAQ
What kind of company is CRDL?
CRDL belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of CRDL?
The market cap of CRDL is approximately $141M, ranking 4,275 within its sector.
What is the 52-week high and low for CRDL?
CRDL has recorded a 52-week high of $2.34 and a low of $0.88.
